Temporary Rhythm Control with Flecainide in Atrial Fibrillation-Related Conversion Pauses Prior to Catheter Ablation: A Case of Successful Pharmacological Bridging
Open Access
- 1 July 2026
- journal article
- case report
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 19, 1-6
Abstract
The management of paroxysmal atrial fibrillation with conversion pauses remains challenging, with catheter ablation and permanent pacemaker implantation representing the main therapeutic strategies. Catheter ablation may eliminate atrial fibrillation paroxysms and prevent conversion pauses, whereas pacemaker implantation combined with antiarrhythmic therapy for rhythm control is another accepted option. We report a case of successful management of paroxysmal atrial fibrillation with conversion pauses using antiarrhythmic agents for rhythm control prior to catheter ablation. A 61-year-old woman had episodes of palpitations, dizziness, and presyncope. Ambulatory 12-lead 24-hour ECG monitoring showed 51 episodes of atrial fibrillation and atrial flutter with conversion pauses after each of them; the longest pause was 7460 ms. Atrial fibrillation lasted for 46.9% of the total monitoring time. When ambulatory 24-hour monitoring was performed, the patient was highly symptomatic (complaints of palpitations and fear of death were predominant, but dizziness episodes were also noted). Catheter ablation was unavailable in the short-term period and permanent pacemaker implantation was not accepted by the patient. Thus, flecainide at a dose of 100 mg BID under close supervision for rhythm control was administered. Also, anticoagulation with edoxaban was provided. The patient remained asymptomatic until ablation was performed. Pulmonary vein isolation with pulsed field ablation and cavotricuspid isthmus ablation was performed 10 days after ambulatory ECG monitoring. There were no paroxysms of atrial fibrillation after ablation. Antiarrhythmic agents in patients with conversion pauses may worsen sinus node function but may also eliminate atrial fibrillation paroxysms preventing conversion pauses. Thus, catheter ablation may be an option for a patient presenting with atrial fibrillation and conversion pauses to avoid unnecessary permanent pacemaker implantation. Short-term pharmacological bridging with flecainide under close supervision may be used in patients with atrial fibrillation and conversion pauses without other signs of sinus node dysfunction, providing effective rhythm control.Keywords
This publication has 18 references indexed in Scilit:
- PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trialEuropean Heart Journal, 2017
- Flecainide: Current status and perspectives in arrhythmia managementWorld Journal of Cardiology, 2015
- Pacing or Ablation: Which Is Better for Paroxysmal Atrial Fibrillation‐Related Tachycardia‐Bradycardia Syndrome?Pacing and Clinical Electrophysiology, 2014
- Pleiotropic actions of amiodarone: still puzzling after half a centuryNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Sinus Bradycardia and Sinus Pauses Immediately after Electrical Cardioversion of Persistent Atrial Fibrillation—What Do They Mean?Annals of Noninvasive Electrocardiology, 2013
- Pulmonary Vein Isolation for Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation and Prolonged Sinus PauseInternational Heart Journal, 2007
- Reversal of Electrical Remodeling After Cardioversion of Persistent Atrial FibrillationJournal of Cardiovascular Electrophysiology, 2004
- Reverse Remodeling of Sinus Node Function After Catheter Ablation of Atrial Fibrillation in Patients With Prolonged Sinus PausesCirculation, 2003
- Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalolThe American Journal of Cardiology, 1993
- Beta-blocking effect of propafenone based on spectral analysis of heart rate variabilityThe American Journal of Cardiology, 1992